Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | REN | P00797 | 2/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.45 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333862 | 0.85 | C5AR1 (0.53) | OPRD1OPRM1SLC6A2RENAGTR1 | |
| SCHEMBL4333867 | 0.85 | C5AR1 (0.53) | OPRD1OPRM1SLC6A2RENAGTR1 | |
| SCHEMBL31332308 | 0.85 | REN (0.64) | RENAGTR1AGTR2 | |
| SCHEMBL29770378 | 0.77 | SLC6A2 (0.62) | SLC6A2RENNTSR1NTSR2SORT1 | |
| SCHEMBL8521196 | 0.77 | CALCRL (0.57) | SLC6A2RENNTSR1NTSR2SORT1 | |
| SCHEMBL30585292 | 0.76 | SLC6A2 (0.60) | OPRD1OPRM1SLC6A2NTSR1NTSR2 | |
| SCHEMBL30512639 | 0.76 | CALCRL (0.59) | SLC6A2RENNTSR1NTSR2SORT1 | |
| SCHEMBL30445678 | 0.76 | SLC6A2 (0.60) | SLC6A2RENNTSR1NTSR2SORT1 | |
| SCHEMBL29548836 | 0.76 | SLC6A2 (0.60) | SLC6A2RENNTSR1NTSR2SORT1 | |
| SCHEMBL31390815 | 0.75 | SLC6A2 (0.56) | OPRD1OPRM1SLC6A2RENNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3506932-B1 | GENETICALLY MODIFIED BACTERIA STABLY EXPRESSING IL-10 AND INSULIN | INTREXON ACTOBIOTICS NV (BE) | 2025-06-25 | — | — | EP | claimed |
| CN-113190056-B | Temperature control method based on slowest link | 扬州工业职业技术学院 | 2022-07-22 | — | — | CN | claimed |
| US-12509518-B2 | Methods and compositions for inhibiting CD32B expressing cells in IgG4-related diseases | XENCOR, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12497457-B2 | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases | XENCOR, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250340650-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES | XENCOR INC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2024223833-A1 | GENETICALLY MODIFIED MICROORGANISM FOR PRODUCING ECTOINE | C-LECTA GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| EP-3468997-B1 | TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B | XENCOR INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230227560-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES | XENCOR, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| CN-114251193-B | Double-component liquid rocket engine integrated propellant storage tank pressurizing system and method | 北京航天动力研究所 | 2023-06-06 | — | — | CN | disclosed |
| CN-115881265-A | Intelligent medical record quality control method, system, equipment and storage medium for electronic medical record | 中国人民解放军总医院第一医学中心 | 2023-03-31 | — | — | CN | disclosed |
| US-20220389098-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES | XENCOR, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-11447552-B2 | Methods and compositions for inhibiting CD32B expressing cells | XENCOR, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11434295-B2 | Methods and compositions for inhibiting CD32B expressing cells | XENCOR, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11365256-B2 | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases | XENCOR, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-11322980-B2 | Inductive power distribution in a vehicle | NISSAN NORTH AMERICA, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114251193-A | Integrated propellant tank pressurization system and method for double-component liquid rocket engine | 北京航天动力研究所 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509518-B2 | Methods and compositions for inhibiting CD32B expressing cells in IgG4-related diseases | FCGR3B, CD22, FCGR1A | OPRD1 3019/4885OPRM1 3909/4885SLC6A2 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.